East Windsor, NJ — A study published in Inflammopharmacology explored how curcuminoids (Sabinsa’s Curcumin C3 Complex and BioPerine) can reduce oxidative stress in patients suffering from type II diabetes, as oxidative stress can add to the development of type II diabetes mellitus (T2DM).
Curcuminoids are natural, chain-breaking antioxidants derived from turmeric-extracted polyphenolic pigments rich in healthy benefits. Curcuminoids are limited by rapid intestinal and hepatic metabolism of its compounds, which is why piperine, an alkaloid, is used for its absorption-enhancing effects. The combination of curcumin and piperine has been tested as safe in previous trials.
The Inflammopharmacology study was completed with 100 participants, 50 of them in a placebo-controlled group. On a daily basis, the non-placebo group was given a 1,000 mg curcuminoid capsule with 10 mg of piperine added to enhance the bioavailability of the curcuminoids. The C3 Complex Curcuminoid in the study was prepared with the three major curcuminoids: curcumin, demethoxycurcumin, and bisdemethoxycurcumin.
Malondialdehyde (MDA) induces low-density lipoprotein modification and is present in those with T2DM. When low levels of superoxide dismutase (SOD) are present, oxidant levels tend to be higher; the same parallel is present in serum total antioxidant capacity (TAC).
At a rate of 1,000mg/curcuminoid blended with 10mg/piperine daily for 3 months, serum MDA was decreased while SOD and TAC activities were increased in patients with T2DM compared with the placebo-controlled group which had reduced SOD and TAC as well as unaltered MDA levels. BMI levels were also decreased in the curcuminoid group in this study.